ClinicalTrialsFinder

TP53 Mutation Clinical Trials in Beijing, Beijing Municipality

1 recruitingBeijing, Beijing Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial CarcinomaTP53 MutationRecurrent or Metastatic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences117 enrolled1 locationNCT06413992